- Home
- SENEA vs IMTX Comparison
SENEA vs IMTX Comparison
Compare SENEA & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- IMTX
- Stock Information
- Founded
- SENEA 1949
- IMTX N/A
- Country
- SENEA United States
- IMTX Germany
- Employees
- SENEA N/A
- IMTX N/A
- Industry
- SENEA Packaged Foods
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SENEA Consumer Staples
- IMTX Health Care
- Exchange
- SENEA Nasdaq
- IMTX Nasdaq
- Market Cap
- SENEA 573.2M
- IMTX 514.2M
- IPO Year
- SENEA N/A
- IMTX N/A
- Fundamental
- Price
- SENEA $82.54
- IMTX $4.26
- Analyst Decision
- SENEA
- IMTX Strong Buy
- Analyst Count
- SENEA 0
- IMTX 4
- Target Price
- SENEA N/A
- IMTX $16.67
- AVG Volume (30 Days)
- SENEA 35.1K
- IMTX 849.5K
- Earning Date
- SENEA 06-12-2025
- IMTX 05-13-2025
- Dividend Yield
- SENEA N/A
- IMTX N/A
- EPS Growth
- SENEA 25.61
- IMTX N/A
- EPS
- SENEA 5.45
- IMTX 0.14
- Revenue
- SENEA $1,541,031,000.00
- IMTX $161,336,577.00
- Revenue This Year
- SENEA N/A
- IMTX N/A
- Revenue Next Year
- SENEA N/A
- IMTX $18.80
- P/E Ratio
- SENEA $15.15
- IMTX $29.39
- Revenue Growth
- SENEA 4.00
- IMTX 188.60
- 52 Week Low
- SENEA $51.79
- IMTX $3.30
- 52 Week High
- SENEA $92.00
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- SENEA 42.15
- IMTX 48.54
- Support Level
- SENEA $82.00
- IMTX $4.03
- Resistance Level
- SENEA $85.20
- IMTX $4.48
- Average True Range (ATR)
- SENEA 3.27
- IMTX 0.39
- MACD
- SENEA -0.66
- IMTX 0.05
- Stochastic Oscillator
- SENEA 14.00
- IMTX 75.00
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.